Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.4731
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 133321926500.0
- FreeCF/Share 1.665
- PFCF 14.1096
- PE 16.9182
- Debt/Assets 0.2946
- DivYield 0.0725
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Are Investors Undervaluing Pfizer (PFE) Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Read More
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure to the field.
Read More
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Published: May 23, 2025 by: MarketBeat
Sentiment: Positive
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Read More
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, …
Read More
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
Read More
Pfizer Looks Like A Great Play At Current Valuations
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, while maintaining solid margins and forward growth expectations. Risks include increased competition in the ATTR-CM market and ongoing technical downtrends, but cost-cutting measures may enhance efficiency.
Read More
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea , May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal …
Read More
Pfizer Thinks Bigger With 3SBio Deal
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows increased control of its oncology pipeline and much higher financial rewards in the long run, and comes at a relatively low cost. The jury is still out on the PD-1/VEGF bispecific antibody class of drugs, but the data to date make this approach worth exploring, and perhaps even necessary.
Read More
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Published: May 20, 2025 by: Investopedia
Sentiment: Positive
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Read More
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
Read More
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Read More
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Read More
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.
Read More
High-Yield Dividend Portfolios Outperform: These Are Our 5 Favorite Stock Picks
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Published: May 18, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
Read More
Pfizer's Turnaround Story Is Stronger Than You Think
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
2 Game-Changing Additions To Your Retirement Income Portfolio
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Retirement income investing should prioritize risk management, income stability, and capital preservation over aggressive growth strategies. To achieve that, investors tend to allocate high-quality value. For example, REITs, infrastructure, midstream and utilities are typical asset classes here.
Read More
New allegations about timing of Pfizer Covid vaccine passed to House panel
Published: May 15, 2025 by: WSJ
Sentiment: Negative
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
Read More
5 Low Price-to-Book Value Stocks to Buy in May
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Read More
PFE vs. LLY: Which Stock Is the Better Value Option?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
Read More
Should Value Investors Buy Pfizer (PFE) Stock?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for investors.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000